🇺🇸

US SEC Filing Intelligence

· daily

Biotech Small-Cap Approvals — April 09, 2026

The FDA approved 17 other products from April 2-6, 2026, with 0 NMEs, 0 biosimilars, 0 label expansions, and all 17 neutral signals in the biotech small-cap stream. A clear dominant theme emerges from clustering: 9 approvals for dapagliflozin across Alembic, Aurobindo Pharma, Micro Labs, Ajanta Pharma Ltd, Macleods Pharms Ltd, Lupin Ltd, Torrent, MSN, and Cipla, alongside 3 approvals for nintedanib esylate by Cipla, Dr Reddys, and Sandoz. Highest-conviction signal is the dapagliflozin cluster (e.g., Cipla and Lupin Ltd approvals), representing bullish entry opportunities for these small-cap generic sponsors into a mature market, balanced by originator revenue erosion risks. Additional singles include glycopyrronium tosylate (Padagis US), phenylephrine hydrochloride (Baxter Hlthcare Corp), and three unknowns (Sandoz Inc, Biocon Pharma Ltd, Inventia Hlthcare). Key risk/watch item: intense multi-sponsor competition in dapagliflozin and nintedanib, potentially compressing entrant margins despite neutral signals.

17 total filings
· daily

New Drug Approvals (Original) — April 09, 2026

The FDA recorded 17 'Other' new drug approvals from April 2-6, 2026 (period defined as April 9), comprising 0 NMEs, 0 biosimilars, 0 label expansions per mix breakdown, with all individual analyses labeled as neutral fallback biosimilar approvals and lacking commercial data. A clear dominant theme emerges in clustered generic/biosimilar entries for dapagliflozin (9 approvals to Alembic, Aurobindo Pharma, Micro Labs, Ajanta Pharma Ltd, Macleods Pharms Ltd, Lupin Ltd, Torrent, MSN, Cipla) and nintedanib esylate (3 approvals to Cipla, Dr Reddys, Sandoz), signaling heightened competition in cardiorenal-metabolic and idiopathic pulmonary fibrosis markets. Highest-conviction signal is the dapagliflozin cluster, bullish for entrant sponsors like Cipla and Lupin Ltd as execution signals in complex generics, bearish for originator AstraZeneca with potential 30-60% Farxiga revenue erosion over 2-3 years. Additional singles include glycopyrronium tosylate (Padagis US), phenylephrine hydrochloride (Baxter Hlthcare Corp), and three unknowns (Sandoz Inc, Biocon Pharma Ltd, Inventia Hlthcare). Key risk/watch item: competitive intensification from multiple dapagliflozin entrants, monitor originator revenue trajectories and generic launch timelines.

17 total filings
· daily

Federal Construction & Infrastructure Contracts — April 09, 2026

These two civilian federal construction contracts total $218,304,799 in obligations, with 0/2 defense-related and focus on Department of Transportation (DOT) and Department of Homeland Security (DHS) infrastructure projects. The highest materiality award is a bullish $95,538,222 firm fixed price delivery order to Brasfield & Gorrie LLC from the U.S. Coast Guard for utility infrastructure, roads, and clinic construction at USCG Base Charleston, SC, signaling substantial medium-term revenue under full and open competition. Kokosing Construction Company, Inc. received a neutral $122,766,577 contract modification from DOT, lacking detailed competitive or risk signals. Dominant theme is civilian agency infrastructure buildout with no defense exposure. Highest-conviction signal is bullish growth for Brasfield & Gorrie amid 3.25-year performance period starting April 2026. Key watch item is Brasfield & Gorrie's outlay progress from $0 current amid high firm fixed price execution risk.

2 total filings
· daily

DHS Homeland Security Contracts — April 09, 2026

DHS awarded $152,669,403 in obligations across two civilian contracts during April 09-09, 2026, with zero defense-related activity. The dominant theme is U.S. Coast Guard infrastructure investment, led by a $95.5 million firm fixed-price design-build contract to Brasfield & Gorrie LLC for utility, roads, and clinic construction at USCG Base Charleston, SC. This full and open competition award provides the highest-conviction bullish signal for Brasfield & Gorrie, estimating ~$29 million annual revenue over 3.25 years starting April 2026. A neutral $57.1 million modification to Paragon Professional Services LLC adds lesser materiality. Key watch item: Brasfield & Gorrie's outlay progress from $0 current obligation amid high firm fixed-price execution risk.

2 total filings
· daily

VA Healthcare & Services Contracts — April 09, 2026

SALIENT CRGT, INC. was awarded a single $205,535,562 firm fixed price Delivery Order by the Department of Veterans Affairs' Technology Acquisition Center NJ for IT network engineering and support services, comprising 100% civilian VA Healthcare & Services obligations with 0 defense-related contracts. The neutral signal (6/10 strength, 7/10 materiality) reflects a competitive full and open win under NAICS 541512, with $101,120,213 already outlayed over ~3 years of the ~5-year period ending 2026-06-21 (potential 2026-09-21), implying ~$41M annual revenue. Substantial subcontracting ($269,012,748 across 43 subawards exceeding prime obligation) tempers direct revenue capture. Highest-conviction signal is established revenue visibility from outlays. Key risk is high pricing risk on the firm fixed price structure amid elevated subawards.

1 total filings
· daily

New Federal Contractors — April 09, 2026

This digest covers 12 new federal contractor awards totaling $1,755,742,802 in obligations from April 9, 2026, with only 1/12 defense-related (CACI's GSA network defense IT contract) and the rest civilian-focused across GSA, VA, NASA, DHS, Treasury, Commerce, and State. Dominant themes include IT systems design and network support, led by GSA and VA with multi-year delivery orders emphasizing cybersecurity and cloud migration. Highest-conviction bullish signal is CACI, Inc. - Federal's $708M cost-plus award for federal enterprise network defense, signaling low-risk revenue through 2024 despite negative outlays to date. Key risk is execution uncertainty from $0 outlays on recent awards like Brasfield & Gorrie LLC's $95.5M DHS construction (starts 2026) and Integral Federal's $61M State printing equipment contract.

12 total filings
· daily

Significant Contract Modifications ($10M+) — April 09, 2026

These 12 significant contract modifications totaling $1,755,742,802 in obligations over April 09, 2026, are overwhelmingly civilian-focused with only 1/12 defense-related, dominated by IT systems design and support services across GSA, VA, NASA, and DHS. Highest-conviction bullish signal is CACI, INC. - FEDERAL's $708M GSA award for federal enterprise network defense, providing low-risk cost-plus revenue through 2024-04-30 despite negative outlays to date. Deloitte Consulting LLP stands out with dual wins totaling $202M from GSA and Treasury for cloud migration and management consulting. Key risk is execution on zero or negative outlays across multiple awards including Brasfield & Gorrie ($96M DHS), Integral Federal ($61M State), and Satsyil ($62M Commerce), signaling potential delays in revenue recognition.

12 total filings
· daily

Contract Deobligations Alert — April 09, 2026

Across 12 contract deobligations alerts totaling $1,755,742,802 in obligations, only 1/12 is defense-related (CACI's GSA network defense award), with the remainder skewed toward civilian agencies including GSA, VA, NASA, DHS, Treasury, Commerce, and State. Dominant themes center on IT systems design, network support, cloud migration, and professional services in civilian sectors, underscoring stable multi-year revenue for tech and consulting firms. Highest-conviction bullish signal is CACI International Inc's $708M GSA delivery order for federal enterprise network defense, with low-risk cost-plus structure despite negative outlays. Key risk is widespread $0 outlays on recent awards like Brasfield & Gorrie LLC's $95M DHS construction and Integral Federal Inc's $61M State printing equipment contracts, signaling potential execution delays amid deobligations. Watch subaward execution exceeding primes (e.g., Salient CRGT Inc's $269M subawards vs. $205M obligation) for margin pressure.

12 total filings
· daily

Contract Option Exercises — April 09, 2026

These 12 contract option exercises totaling $1,755,742,802 in obligations (1/12 defense-related, 11/12 civilian) highlight civilian agency dominance, with GSA, VA, NASA, and DHS leading IT services, engineering support, and construction awards. Dominant themes include federal IT network defense and cloud migration, exemplified by CACI's $708M GSA award as the highest-conviction bullish signal for stable, low-risk revenue through 2024. Deloitte Consulting LLP shows concentration with $202M across GSA and Treasury wins, signaling consulting strength. Key risk is execution uncertainty from negative outlays (CACI -$453K) and zero outlays on fresh awards like Brasfield & Gorrie ($95M DHS) starting 2026. Watch multi-year performance ends in 2026-2029 for option exercises and funding progress.

12 total filings
· daily

Federal Professional Services Contracts — April 09, 2026

These two civilian federal professional services contracts total $213,317,405 in obligations, with zero defense-related awards, highlighting NASA and Treasury Department spending on engineering and management consulting. HALVIK, LLC secured the highest-materiality award at $132,970,632 from NASA for enterprise-wide procurement support, a neutral signal as an 8(a) set-aside win with $102.4M already outlayed. Deloitte Consulting LLP's $80,346,773 Treasury BPA call for intelligence analysis is the highest-conviction bullish signal, reflecting strong execution with $62.6M outlayed in a full-and-open competition firm-fixed-price vehicle. Dominant theme is sustained civilian agency demand for support services amid ongoing performance through 2026. Key watch item: track option exercises for both contracts toward ceilings of $148.8M (HALVIK) and $101.3M (Deloitte) to gauge revenue upside.

2 total filings
· daily

Federal IT & Cybersecurity Contracts — April 09, 2026

Four federal IT and cybersecurity contracts totaling $1,097,635,237 in obligations, with 1/4 defense-related, highlight civilian agency dominance via GSA awards comprising ~75% of value ($830M to CACI and Deloitte). Highest-conviction bullish signal is CACI International Inc's $708M GSA cost-plus network defense delivery order, signaling low-risk multi-year revenue stability. VA and Commerce add neutral signals via Salient CRGT ($206M) and Satsyil Corp ($62M) for IT infrastructure and data services. Dominant theme is sustained civilian IT modernization amid cloud migration and network support needs. Key watch item: outlay progress across contracts, including CACI's negative $-453K and Satsyil's $0 outlays, amid option exercises and 2024-2030 end dates.

4 total filings
· daily

Mega Contracts Monitor ($100M+) — April 09, 2026

This week's Mega Contracts Monitor captures $1,291,393,992 in total obligations across 5 awards, with 1 defense-related and 4 civilian-focused contracts emphasizing federal IT services. GSA dominates with two high-value awards to CACI ($708M) and Deloitte ($122M), signaling robust demand for network defense and cloud migration in civilian agencies like GSA, VA, NASA, and DOT. The highest-conviction bullish signal is CACI's $708M cost-plus GSA delivery order for enterprise network defense, offering low-risk multi-year revenue through 2024. Neutral signals prevail in VA, NASA, and DOT contracts, with balanced execution via significant outlays in Salient CRGT ($101M) and Halvik ($102M). Key risk: Negative or low outlays in top materiality contracts like CACI (-$453k) and Deloitte (-$10k), warranting watch on spending progress amid potential adjustments.

5 total filings
· daily

High-Value Federal Grants ($5M+) — April 09, 2026

These 12 high-value federal contracts total $1,755,742,802 in obligations, with only 1/12 defense-related (CACI's GSA network defense award) and the remaining 11 civilian-focused across agencies like GSA, VA, NASA, DHS, Treasury, Commerce, and State. Dominant theme is multi-year IT systems design, network support, and professional services, led by CACI ($708M), SALIENT CRGT ($206M VA), and HALVIK ($133M NASA). Highest-conviction bullish signal is CACI's $708M cost-plus GSA delivery order for federal enterprise network defense, offering low-risk ~$141M annual revenue through 2024 with potential $1.03B ceiling. Balanced by neutral signals on most awards; key risk is stalled outlays, including CACI's negative $-453K and zero outlays on $368M+ across Brasfield & Gorrie ($96M DHS), SATSYIL ($62M Commerce), Integral Federal ($61M State), and ATT Mobility ($54M State).

12 total filings
· daily

General Federal Contracts — April 09, 2026

Across 12 contracts totaling $1,755,742,802 in obligations from April 09, 2026 data, only 1/12 is defense-related (CACI's GSA network defense award), with the remainder dominated by civilian agencies including GSA, VA, NASA, DHS, Treasury, Commerce, and State. IT services and support emerge as the dominant sector theme, comprising high-materiality awards like CACI's $708M and SALIENT CRGT's $206M. Highest-conviction bullish signal is CACI International Inc's $708M GSA cost-plus award for federal enterprise network defense, offering low-risk multi-year revenue despite negative outlays to date. Key risk is execution on firm-fixed-price contracts like Brasfield & Gorrie's $96M DHS construction award, carrying high pricing risk with $0 outlayed and performance starting 2026-04-20.

12 total filings
· daily

All NASA Contracts — April 09, 2026

NASA dominates this $132,970,632 obligation period with a single high-materiality award to HALVIK, LLC, representing 100% civilian exposure and 0% defense-related contracts. The dominant theme is NASA enterprise-wide procurement support services under an 8(a) competed set-aside delivery order. Highest-conviction signal is neutral, reflecting steady outlays of $102.43M to date on this cost-plus award fee vehicle with low pricing risk. HALVIK, a private 8(a)/EDWOSB firm, benefits from $58.86M in subawards across 48 recipients, but the contract nears its current 2026-04-30 end date. Key watch item: progress toward full $148.76M base-plus-options value and potential extension to 2026-11-30.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 09, 2026

Across 17 filings in the USA S&P 500 Technology stream (broadly interpreted to include adjacent sectors like biotech and software), proxy statements dominate (10/17 filings) signaling routine Q2 2026 AGM season with record dates in March-April and meetings clustered May 19-27, 2026, offering low-materiality governance catalysts. Strong revenue acceleration stands out in biotech/software: ImmunityBio's Q1 2026 net product revenue surged 168% YoY to $44.2M (+15% QoQ) and GameSquare's Q4 2025 revenue jumped 142% YoY to $18.5M with first positive adjusted EBITDA; Simulations Plus Q2 FY2026 revenue +8% YoY to $24.3M but H1 only +3% with EPS guidance cut. Mixed signals include Camden Property Trust's $53M antitrust settlement (no FFO impact) and GameSquare's widened net loss; DNOW's MRC Global acquisition adds $70M synergies. No widespread insider selling or capital allocation shifts noted, but positive forward-looking catalysts like ImmunityBio's supplemental BLA and GameSquare's $85-90M 2026 revenue guide point to growth pockets amid neutral proxy noise. Portfolio-level trends show 3/4 key metric reporters with YoY revenue growth averaging +104% but variable profitability (e.g., GameSquare +EBITDA margin to 9.4%, Simulations +66% gross margin). Implications favor selective longs in high-growth outliers like ImmunityBio while monitoring guidance risks in Simulations Plus.

8 high priority 9 medium 17 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 09, 2026

The April 9, 2026, filings from NASDAQ-100 related entities are dominated by proxy statements (13/20) for May 2026 AGMs, signaling peak proxy season with routine governance votes on directors, auditors, and compensation, mostly neutral but highlighting board continuity and virtual/in-person formats. Key financial highlights include ImmunityBio's explosive Q1 2026 revenue growth of 168% YoY to $44.2M and 15% QoQ, bolstering cash to $380.9M amid trial progress, contrasting Simulations Plus' mixed Q2 FY2026 results (8% YoY revenue to $24.3M, 47% net income growth) but lowered FY2026 EPS guidance to $0.75-$0.85 from $1.03-$1.10 due to tax hikes. Camden Property Trust's $53M antitrust settlement is one-time with no FFO impact, while AITX announced a new AI product positively. Portfolio-level trends show biotech outperformance (ImmunityBio +168% YoY vs Simulations H1 +3%), limited insider activity (only Adial comp grants), no major capital allocation shifts, and forward catalysts clustered in May AGMs and ImmunityBio's 2026 sBLA. Overall, low volatility with biotech alpha opportunities amid neutral governance noise.

9 high priority 11 medium 20 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 09, 2026

Across 50 filings from the USA S&P 500 Financials stream (with broader equity exposure), proxy season dominates with 10+ DEFA14A/DEF14A filings urging votes for May 2026 annual meetings, signaling routine governance but heightened attention via virtual formats and board recommendations FOR key items like auditors and comp. Period-over-period trends show stark divergence: Piper Sandler reported robust 2025 adj net income +39% YoY to $318M and rev $1.88B (2nd highest), contrasting sharp declines like Beyond Meat's -15.6% YoY rev to $275M and gross margin collapse to 2.8% from 12.8%; Resources Connection rev -16.6% YoY but Q3 net loss narrowed to $9.5M from $44.1M. Capital allocation highlights include News Corp's ongoing $1B stock repurchase and Piper's 4:1 stock split; 13F-HR filings (11 total) from managers like Lakehouse Capital ($148M AUM, tech-heavy) and LPWM LLC ($396M AUM) reveal persistent overweight in tech giants (Amazon, MSFT, NVDA) and ETFs, implying defensive portfolio tilts. Mixed sentiments prevail (neutral dominant, pockets of positive like Abra SPAC optimism and abrdn fund reorganization for 30-50% high-yield munis), with forward catalysts clustering in May meetings and SPAC mergers; risks from going concerns (Ensysce cash to Q2 2026) and proxy contests (Gabelli vs Saba). Overall, financials exhibit resilience via buybacks/splits amid broader weakness in consumer/revenue contraction names, favoring selective longs in strong performers like Piper.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 09, 2026

The 50 filings for USA S&P 500 Consumer Staples reveal a heavy focus on proxy season with 20+ DEF/DEFA14A materials clustering AGMs in May 2026 (e.g., PG&E May 21, NIQ May 21, Ellington May 28), emphasizing governance, director elections, and incentive plans amid neutral sentiment. Financial trends mixed across limited data points: GCL Global revenue surged 45.7% YoY to $142M with profitability turnaround, contrasting Mobile-health's 45.3% YoY revenue drop and 84.6% cash decline; PG&E highlighted ops gains (40% fewer ignitions YoY, dividend doubled to $0.20/share) and 9%+ EPS guidance. M&A/SPAC deals dominate positive catalysts (Mountain Lake $3.25B quantum LOI, Constellation $571M lithium combo), while 13F-HR filings (8 total) show institutional stability in ETFs/large-caps like Apple, S&P 500. Consumer Staples specifics limited but actionable: Colgate smooth CLO transition June 1, Scotts Miracle-Gro monetizes Hawthorne via Vireo shares. Capital allocation leans shareholder-friendly (dividend hikes, buybacks proposed), but delistings (Actelis Apr 10) and compliance risks flag volatility. Portfolio implication: monitor May catalysts for staples governance, favor deal-exposed names for alpha.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 09, 2026

The 50 filings for USA S&P 500 Industrials stream are dominated by proxy statements (DEF 14A/DEFA14A) for May 2026 AGMs, signaling peak proxy season with routine governance votes on directors, compensation, and auditors across 20+ companies including PHINIA, SBA Communications, and Photronics. Financial disclosures are sparse but reveal mixed period-over-period trends: revenue growth in PHINIA (33% TSR outperforming sector), GCL Global (+45.7% YoY to $142M), and Better Home (+89% YoY loan volume), contrasted by declines in Neogen (-4.4% YoY Q3 to $211.2M, Animal Safety -20.1%), Beam Global (cash burn worsened to -$10.5M), and Sunshine Biopharma (net loss widened to $6M despite +4.1% rev). No insider trading activity reported; capital allocation highlights PHINIA's >20% share buybacks post-spin and Neogen's $160M Genomics divestiture (net $140M proceeds, debt down $81.5M). Forward-looking includes Neogen's raised FY2026 rev guidance ($857-860M) and multiple global trials/M&A. Sector implications: Industrials like PHINIA/Photronics show resilience via buybacks/shareholder approvals; watch deleveraging and May catalysts for alpha amid governance focus.

21 high priority 29 medium 50 total filings